Clinical Trial

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2024 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of cadonilimab combined with AK112 as second-line therapy in patients with advanced hepatocellular carcinoma.
Trial Details
NCT Number NCT06196775
Lead Sponsor Harbin Medical University
Conditions Hepatocellular Carcinoma
Enrollment 36 participants
Start Date 2024-01-31
Primary Completion 2026-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-09